<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>How Renewed Scrutiny of Pediatric Vaccine Safety at Moderna (MRNA) Has Changed Its Investment Story</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>How Renewed Scrutiny of Pediatric Vaccine Safety at Moderna (MRNA) Has Changed Its Investment Story</h1>
  <ul>
<li>This requires 4.6% yearly revenue growth and a $3.4 billion increase in earnings from current earnings of -$2.9 billion.</li>
<li>Uncover how Moderna's forecasts yield a $44.25 fair value , a 85% upside to its current price.</li>
<li>Read the full narrative on Moderna (it's free!) Moderna's narrative projects $3.5 billion revenue and $498.6 million earnings by 2028.</li>
<li>Story Continues MRNA Community Fair Values as at Sep 2025 Twenty-six members of the Simply Wall St Community estimate Moderna’s fair value between US$44.25 and US$186.49 a share.</li>
<li>Explore 26 other fair value estimates on Moderna - why the stock might be worth just $44.25!</li>
<li>In early September 2025, news emerged that Trump administration health officials planned to present claims linking COVID-19 vaccines to the deaths of about two dozen children, prompting heightened regulatory and public s</li>
<li>Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/renewed-scrutiny-pediatric-vaccine-safety-110634823.html">Source</a> · 2025-09-16T11:06:34+00:00</p>
</body>
</html>